AbbVie announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes.
[More]
Despite previous studies touting its benefit in moderating gout risk, new research reveals that vitamin C, also known ascorbic acid, does not reduce uric acid (urate) levels to a clinically significant degree in patients with established gout. Vitamin C supplementation, alone or in combination with allopurinol, appears to have a weak effect on lowering uric acid levels in gout patients according to the results published in the American College of Rheumatology (ACR) journal, Arthritis & Rheumatism.
[More]
Individuals with diabetes may reduce their risk for developing nephropathy if they minimize their exposure to persistent organic pollutants, suggest researchers.
[More]
The standard approach to detecting chronic kidney disease fails to spot the condition in about a quarter of patients with hypertension, a study suggests.
[More]
Individuals with Type 1 diabetes should keep good control of their blood sugar levels and blood pressure to reduce their risk for developing nephropathy, say researchers.
[More]
New data from two clinical trials presented today at the International Liver Congress- 2013 demonstrate substantial improvements in the detection of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) using diagnostic urine tests.
[More]
Researchers may have found a way to block kidney-destroying inflammation and help damaged kidney cells recover.
[More]
Exposure to tobacco smoke could negatively impact adolescent kidney function; this is according to a new study led by a team of researchers at the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins Children's Center.
[More]
Bristol-Myers Squibb Company announced today that 14 abstracts on the Company's research in liver disease have been accepted for presentation at The International Liver CongressTM 2013, the 48th annual meeting of the European Association for the Study of the Liver, in Amsterdam, April 24 - 28.
[More]
With previous evidence suggesting that melatonin may have a role in glucose metabolism, researchers have found an independent association between decreased secretion of melatonin and an increased risk for the development of type 2 diabetes, according to a study in the April 3 issue of JAMA.
[More]
Cytori Therapeutics received US Patent No. 8,404,229 (the '229 patent) for methods of treating renal diseases using adipose-derived regenerative cells (ADRCs).
[More]
A guidance cue that helps kidneys form may also be a red flag that they are in danger, researchers report.
[More]
High doses of a popular cholesterol-lowering drug significantly reduced the rate of acute kidney injury caused by dye used in imaging in acute coronary syndrome patients who underwent a coronary procedure, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
[More]
Urinary cystatin C level may be a useful biomarker for discriminating between prerenal and intrinsic acute kidney injury, report researchers.
[More]
Guerbet, the contrast agent specialist for medical imaging, today announced that the Medical Imaging Drugs Advisory Committee to US Food and Drug Administration (FDA) has voted unanimously by votes of 17 to 0 to recommend that FDA approve the New Drug Application (NDA) for Dotarem (gadoterate meglumine) for adults, and for pediatric use for children two years of age and older.
[More]
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
[More]
Patients’ estimated glomerular filtration rate is highly predictive of their risk for dying after surgery, shows a systematic review and meta-analysis.
[More]
Pfizer Inc. said today that the United States District Court for the District of Delaware ruled that Pfizer's patent covering a method for using sirolimus, the active ingredient in RAPAMUNE®, for the inhibition of organ transplant rejection is valid and infringed.
[More]
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.
[More]